<DOC>
	<DOCNO>NCT00510250</DOCNO>
	<brief_summary>This multi-institution , single-arm , open-label , phase I/II trial . Eligible patient pathologically-proven T1b-3b , N0/1 , M0 epithelial carcinoma cervix . We hypothesize sorafenib combination chemotherapy radiotherapy may anti-tumor activity patient cervical cancer . Sorafenib previously combine conventional RT-CT treat cervix cancer .</brief_summary>
	<brief_title>A Phase I/II Study Cisplatin Radiation Combination With Sorafenib Cervical Cancer</brief_title>
	<detailed_description>During phase I component study , low risk patient ( tumor size â‰¤5 cm radiographically node negative ) receive sorafenib alone escalate dos least 1 week prior start conventional treatment radiotherapy chemotherapy ( RT-CT ) . High risk patient ( tumor &gt; 5 cm node positive ) receive sorafenib alone escalate dose least 1 week prior start RT-CT , well concurrently RT-CT . Cohorts 3 patient per dose level plan . If 1/3 patient encounter dose-limiting toxicity ( DLT ) , cohort expand 6 patient . If &gt; 2/3 patient encounter DLT , dose level declare maximum tolerate dose ( MTD ) . An additional 3 patient enter dose level one MTD . The recommended phase II dose ( RPTD ) define dose level &lt; 1/6 patient DLT . For phase II component , patient receive sorafenib RPTD least 1 week prior , concurrent , RT-CT .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must biopsyproven epithelial carcinoma cervix , T1B3B , N0/1 , M0 visible palpable disease decision treat radically radiotherapy concurrent cisplatin chemotherapy ( RTCT ) . ECOG performance status 0 , 1 2 ( Karnofsky &gt; =60 % ) Life expectancy great 12 week . Patients must normal organ marrow function define : Leukocytes &gt; 3,000/mcL Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL Hemoglobin &gt; 9 g/dL Total bilirubin Within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; =2.5 X institutional upper limit normal Creatinine Within normal institutional limit , Creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level normal No prior treatment cervix cancer . The effect sorafenib develop human fetus recommend therapeutic dose unknown . Although radical RTCT cervix cancer compatible survival develop fetus , woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . No active malignancy another site . Ability understand willingness sign write informed consent document Patients may receive investigational agent concurrently within 4 week . Patients previous exposure rafkinase inhibitor exclude Patients poorly control hypertension ( systolic blood pressure 140 mmHg high , diastolic blood pressure 90 mmHg high ) ineligible . Patients condition impairs ability swallow sorafenib tablet exclude ( e.g . gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) . Bleeding disorder . Patients receive therapeutic anticoagulation . Prophylactic anticoagulation ( ie . low dose warfarin ) venous arterial access device allow provided requirement PT , INR , PTT meet . Patients know brain metastasis exclude poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . These patient would eligible radical RTCT cervix cancer , instead would treat palliation . Patients intercurrent cardiac dysfunction include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia exclude history ischemic heart disease include myocardial infarction . Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study sorafenib potential teratogenic abortifacient effect show gross fetal malformation effect embryofetal survival see reproductive toxicity study rat . Because unknown potential risk adverse event nurse infant secondary treatment mother sorafenib , breastfeed discontinue mother treated sorafenib . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction sorafenib . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate . A decision treat extendedfield pelvic paraaortic radiotherapy , specifically case paraaortic field extend cranial L34 vertebral interspace .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cervix Cancer</keyword>
	<keyword>Cervical Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Radiation</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Cervix</keyword>
</DOC>